Pharmacologics/dietary supplements targeting pain mechanisms tested in mice and/or patients with sickle cell disease
| Generic name . | Mechanistic target . | Action . | Sickle subjects . | |
|---|---|---|---|---|
| Mice . | Humans . | |||
| A-425619 | TRPV1 | Antagonist | X | |
| AT-200 | NOP/R and MOR | Agonist | X | |
| Bosentan | ET-A and ET-B receptors | Antagonist | X | X |
| Coenzyme Q10 | Oxidative stress | Inhibitor | X | X |
| CP55940 | CB1R and CB2R | Agonist | X | |
| Crizanlizumab | P-selectin | Antibody | X | |
| Cromolyn | Mast cell | Stabilizer | X | X |
| Curcumin | ROS | Inhibitor | X | X |
| Duloxetine | Serotonin and norepinephrine reuptake transporter | Inhibitor | X | X |
| HC-030031 | TRPA1 | Antagonist | X | |
| Imatinib | Mast cell/c-kit/RTK | Inhibitor | X | X |
| KN-93 | CaMKII | Inhibitor | X | |
| l-arginine | NOS | Substrate | X | |
| l-glutamine | Oxidative stress | Antioxidant | X | |
| Lovastatin | HMG-CoA reductase | Inhibitor | X | |
| PEG-ADA | Adenosine | Inhibitor | X | |
| Rapamycin | mTOR | Inhibitor | X | |
| HbF | Inducer | |||
| Simvastatin | HMG-CoA reductase, calpain-1 | Inhibitor | X | X |
| Sivelestat | Neutrophil elastase | Inhibitor | X | |
| TAK-242 | TLR4 | Inhibitor | X | |
| Trifluoperazine | CaMKIIα | Inhibitor | X | X |
| ω-3 fatty acid | Oxidative stress | Antioxidant | X | X |
| Generic name . | Mechanistic target . | Action . | Sickle subjects . | |
|---|---|---|---|---|
| Mice . | Humans . | |||
| A-425619 | TRPV1 | Antagonist | X | |
| AT-200 | NOP/R and MOR | Agonist | X | |
| Bosentan | ET-A and ET-B receptors | Antagonist | X | X |
| Coenzyme Q10 | Oxidative stress | Inhibitor | X | X |
| CP55940 | CB1R and CB2R | Agonist | X | |
| Crizanlizumab | P-selectin | Antibody | X | |
| Cromolyn | Mast cell | Stabilizer | X | X |
| Curcumin | ROS | Inhibitor | X | X |
| Duloxetine | Serotonin and norepinephrine reuptake transporter | Inhibitor | X | X |
| HC-030031 | TRPA1 | Antagonist | X | |
| Imatinib | Mast cell/c-kit/RTK | Inhibitor | X | X |
| KN-93 | CaMKII | Inhibitor | X | |
| l-arginine | NOS | Substrate | X | |
| l-glutamine | Oxidative stress | Antioxidant | X | |
| Lovastatin | HMG-CoA reductase | Inhibitor | X | |
| PEG-ADA | Adenosine | Inhibitor | X | |
| Rapamycin | mTOR | Inhibitor | X | |
| HbF | Inducer | |||
| Simvastatin | HMG-CoA reductase, calpain-1 | Inhibitor | X | X |
| Sivelestat | Neutrophil elastase | Inhibitor | X | |
| TAK-242 | TLR4 | Inhibitor | X | |
| Trifluoperazine | CaMKIIα | Inhibitor | X | X |
| ω-3 fatty acid | Oxidative stress | Antioxidant | X | X |
ETA and ETB, endothelin A and endothelin B; CB1R/CB2R, cannabinoid receptor 1/2; HMG-CoA reductase, 3-hydroxy-3-methyl-glutaryl–coenzyme reductase; NE, norepinephrine; NOS, nitric oxide synthase; PEG-ADA, polyethylene glycol–modified adenosine deaminase; TRPA1, transient receptor potential cation channel subfamily A, member 1.